Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Dependence on Lab Animals for Testing Asthma and Allergy Agents Reduced with 3D Test

By BiotechDaily International staff writers
Posted on 13 Apr 2014
In a recent study, scientists report that they’ve developed a simple, three-dimensional (3D) laboratory technique to test asthma and allergy medications that mimics what occurs in the body, which could help reduce the need for animal testing.

Dr. Amir Ghaemmaghami and colleagues from the University of Nottingham (UK) noted that respiratory disorders, such as asthma and allergies, are becoming more common. These conditions affect the lungs and the airway leading to the lungs, making it difficult to breathe. Respiratory symptoms lead to expensive hospital visits, as well as absences from work and school. Improved agents could provide better relief, but before giving new medicines to people, researchers must first test them in animals—an expensive and arduous process. Sometimes, researchers will use 2D tests in which they apply the drug to a layer of human cells in a lab dish instead, but this is not a satisfactory way to tell how a pharmaceutical agent will perform in a whole animal or a whole individual. Therefore, Dr. Ghaemmaghami’s team developed a new, 3D alternative.

Their test includes three types of human cells that are typically in a person’s airway. In the body, these cells are close together and are involved in the development of respiratory conditions. The 3D model reacted similar to an actual person’s airway when they exposed it to allergens and bacterial extract. They say that the model has the potential of reducing the need for some animal testing of new drugs for respiratory conditions.

The study’s findings were published March 14, 2014, in the ACS’ journal Molecular Pharmaceutics.

Related Links:

University of Nottingham



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.